Drug Trial Radar · NCT04150614
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
May 14, 2020
Primary completion
Mar 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- University of Illinois ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.
Conditions
- Nausea With Vomiting Chemotherapy-Induced
Interventions
Granisetron Transdermal PatchDrug
Antiemetic
Intravenous DexamethasoneDrug
Antiemetic
OndansetronDrug
ondansetron
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the acute period (0-24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.Time frame: 0 hours to 24 hours post-chemotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.